-2002 14:56 From-BROWDY NI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Hagit AMITAI, et al

Art Unit: 1646

Application No.: 09/807,610

Conf. No.2065

Examiner: Ruixiang Li

Fited: April 16, 2001

Washington, D.C.

For: EXPRESSION AND SECRETION OF ICIL-1 RECEPTOR ANTAGONIST TYPE II

Atty.'s Docket: AMITAI=1

Date: October 2, 2002

BY FACSIMILE

ÓR

OR

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Transmitted herewith is a [] Amendment [XX] Supplemental Preliminary Amendment in the above-identified application.

- [] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
- [XX] No additional fee is required.
- I The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)					
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS				
TOTAL	16	MINUS	~ 20	0				
INDEP.	2	MINUS	3	0				
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM								

_	SWALL CHILL					
		RATE	ADDITIONAL FEE			
_	x_	9	\$			
	х	42	\$			
	+	140	ş			
ADDITIONAL FEE TOTAL			\$ ·			

Other Than Small Entity

OTHER THAN SMALL ENTITY ADDITIONAL 18 84 \$ 5

- If the entry in Coi, 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

Small Entity

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby patitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	Single Endty	•	Outer Than Officer Entry			
	Response Filed Within	R	Response Filed Within			
	[] First - \$ 55.00	1] First	- \$ 110.00		
	[] Second - \$ 200,00	1] Second	- \$ 400 00		
	[] Third - \$ 460.00	1] Third	- \$ 920,00		
	[] Fourth - \$ 720 00	1] Fourth	- \$ 1440.00		
	Month After Time Period Set	onth After Time	After Time Period Set			
, ,	[] Less fees (\$) already paid for month			_ ·		
[]	Please charge my Deposit Account No. 02-4035 in the a	mount ar ş	-			
()	Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$					
[]	A check in the amount of \$ is attached	(check ná.).				
(XX)	The Commissioner is hereby authorized and requested t	o cnarge any additional fee	s which may be	required in conn		

nection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.18 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attomevs for Applicant(s)

Allen C. Yun Registration No. 37,971

(202) 737-3529 (202) 628-5197 Talephone:

10/7/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: AMITAI=1

In re Application of:

Hagit AMITAI, et al

Appln. No.: 09/807,610

Filed: April 16, 2001

For: EXPRESSION AND SECRETION
OF ICIL-1 RECEPTOR
ANTAGONIST TYPE II

Conf. No.: 2065

AMITAI=1

Art Unit: 1646

Examiner: Ruixiang Li

Washington, D.C.

October 2, 2002

BY FACSIMILE

SUPPLEMENTAL PRELIMINARY AMENDMENT

Honorable Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend as follows:

IN THE CLAIMS

Please replace claim 9 with new amended claim 9 as follows below. A marked up version of the amended claim to show the changes made is attached hereto.

9(Once-amended). A glycosylated icIL-lra-II produceable by a method according to claim 7.

Please add new claim 16 as follows:

--16(New). Glycosylated icIL-1ra-II.--